)
Odinwell (ODIN) investor relations material
Odinwell Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 focus shifted from product development toward commercialization, with novaQS veterinary launch targeted for Q4 2026 and two global wound-care actors evaluating the platform.
After quarter-end, one global wound-care actor provided a Letter of Intent and another began an additional evaluation collaboration; a new patent application was filed in November.
Financial highlights
Q3 2026 revenue was SEK 816k vs. SEK 988k YoY; operating loss was SEK 1.442m vs. SEK 1.501m, and net loss was SEK 1.442m vs. SEK 1.400m.
Q3 EPS was -SEK 0.02 vs. -SEK 0.04 YoY; 9M revenue was SEK 2.580m vs. SEK 3.079m, operating loss SEK 4.052m vs. SEK 4.971m, and net loss SEK 4.027m vs. SEK 4.807m.
9M EPS was -SEK 0.05 vs. -SEK 0.12; cash and cash equivalents were SEK 2.957m at Sep. 30, 2026, vs. SEK 3.485m a year earlier.
Outlook and guidance
CE marking and launch of novaQS for the veterinary market remained targeted for Q4 2026; results from the horse study are expected to support product use and marketing.
Commercial focus is moving toward market entry, with further customer, distributor and strategic-partner discussions underway in Sweden and internationally.
- First commercial sales mark progress toward market launch, with improved financial results.ODIN
Q2 2026 - Veterinary focus accelerates commercialization, with improved results and strong equity position.ODIN
Q1 2026 - Revenue fell, losses narrowed, and commercialization in veterinary medicine is prioritized for 2026.ODIN
Q4 2025 - Stable revenue, continued losses, strong equity, and key R&D milestones achieved.ODIN
Q3 2025 - Revenue declined and losses continued, but clinical and technical milestones were achieved.ODIN
Q2 2025 - Q3 saw narrowed losses, strong cash position, and key product development milestones reached.ODIN
Q3 2024 - Stable losses and modest revenue growth as Odinwell advances wound care sensor development.ODIN
Q2 2024 - Q1 saw stable losses, new funding, and clinical progress as Odinwell targets growth.ODIN
Q1 2025 - Improved results and strategic progress in wound care tech mark Odinwell's 2024.ODIN
Q4 2024
)
)
)
)
)
)
)
)